The Trouble With Pay-for-Performance
P4P Incentives Too Small
Another problem is if the incentives need to be larger, where is the money going to come from? Very few commercial insurers want to add new money so that means moving away from bonuses. After all, the larger goal is to reduce the cost growth of healthcare. New bonus money has to come from somewhere. Meanwhile, Medicare is trying to do incentives that are budget-neutral, Ryan says.
"The problem here is if we went to 5% or 10% [of revenues], that would get attention, but risk disadvantaging certain types of providers like the safety net. Some could get penalized a lot," he says. "It's a classic trade-off and I'm not sure what the sweet spot is as to the level of incentive anyway."
Another problem with getting traction from P4P on improving value is that such programs focus on process measures instead of outcomes, Ryan says. But measuring outcomes presents its own set of complications, which is one reason why P4P still gets so much attention.
"Providers often don't like outcomes because they argue they are largely out of their control," he says, adding that performance on outcomes measures is quite noisy statistically, "so you might have a rate that looks good one year and bad the next and is a result of statistical noise. There's not much of a quality signal there."
The other problem, of course, is that incentivizing outcomes also creates incentives to avoid providing care for certain types of patients.
"We have risk adjustment, and if it was perfect, we wouldn't have people contending reimbursement on outcomes is unfair, but it's not and never will be," says Ryan.
- Two-Midnight Rule Must be Fixed or Replaced, Say Providers
- Don't Underestimate Emotional Intelligence
- The Secret to Physician Engagement? It's Not Better Pay
- Care Coordination Tough to Define, Measure
- SCOTUS Review of NC Board Case 'A Very Big Deal' to Providers
- Yale New Haven Health Partners with Tenet Healthcare in CT
- CDC Warns of Antibiotic Overuse in Hospitals
- Physicians Take SGR Repeal Message to Washington
- Size Matters in Antibiotic Overuse
- Excluded Benefits Lists Spark Debate